Clinical Trials

Study Title:
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

For more information about the trial above please contact the study team:

Medical University of South Carolina
Principal Investigator, Theodore Gourdin, at gourdith@musc.edu.
Study Coordinator, Holly Boggan, at bogganhl@musc.edu, or please call +1 843-792-8068.

Trial opened at the following institutions: Medical University of South Carolina